title: Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia.
abstract: CD52 is a glycoprotein expressed on normal as well as leukemic immune cells and shed as soluble CD52 (sCD52). We studied sCD52 levels in three CLL cohorts: the 'early', the 'high-risk', and the 'ibrutinib-treated'. The 'high-risk' patients had significantly higher sCD52 levels than the 'early' patients. For the 'early' patients, high sCD52 levels were associated with a significantly shorter time to first treatment. Regarding prognostic factors, no clear correlations with stage, IGHV, or beta-2-microglobulin were found; in a cox multivariate analysis of the 'early' patients, sCD52 and IGHV both had independent prognostic value. Following chemo-immunotherapy, sCD52 decreased in parallel with leukocytes while during ibrutinib treatment and ibrutinib-induced ymphocytosis, sCD52 decreased along with lymph node reductions. In vitro IgM stimulation of CLL cells led to increased sCD52 levels in the medium. Our findings indicate that sCD52 reflects disease activity and potentially treatment efficacy in CLL.
authors.affiliation: a Department of Hematology , Rigshospitalet , Copenhagen , Denmark.|b Department of Clinical Biochemistry , Bispebjerg-Frederiksberg Hospital , Copenhagen , Denmark.
authors.forename: Fie J
authors.initials: FJ
authors.lastname: Vojdeman
authors.affiliation: c Hematology Branch, National Heart, Lung, and Blood Institute , National Institutes of Health , Bethesda , MD , USA.
authors.forename: Sarah E M
authors.initials: SEM
authors.lastname: Herman
authors.affiliation: d Department of Microbiology , Rigshospitalet , Copenhagen , Denmark.
authors.forename: Nikolai
authors.initials: N
authors.lastname: Kirkby
authors.affiliation: c Hematology Branch, National Heart, Lung, and Blood Institute , National Institutes of Health , Bethesda , MD , USA.
authors.forename: Adrian
authors.initials: A
authors.lastname: Wiestner
authors.affiliation: e Department of Hematology , Leiden University Medical Centre , Leiden , The Netherlands.
authors.forename: Mars B
authors.initials: MB
authors.lastname: van T' Veer
authors.affiliation: f Department of Hematology , Oslo University Hospital and Institute of Clinical Medicine, University of Oslo , Oslo , Norway.
authors.forename: Geir E
authors.initials: GE
authors.lastname: Tjønnfjord
authors.affiliation: g Department of Hematology , Turku Central University Hospital , Turku , Finland.
authors.forename: Maija A
authors.initials: MA
authors.lastname: Itälä-Remes
authors.affiliation: h Division of Hematology, Department of Medicine at Huddinge , Karolinska Institute , Stockholm , Sweden.
authors.forename: Eva
authors.initials: E
authors.lastname: Kimby
authors.affiliation: c Hematology Branch, National Heart, Lung, and Blood Institute , National Institutes of Health , Bethesda , MD , USA.
authors.forename: Mohammed Z
authors.initials: MZ
authors.lastname: Farooqui
authors.affiliation: i Department of Hematology , Hadassah University Hospital, Hebrew University Medical School , Jerusalem , Israel.
authors.forename: Aaron
authors.initials: A
authors.lastname: Polliack
authors.affiliation: j Department of Hematology , Stuivenberg Hospital , Antwerpen , Belgium.
authors.forename: Ka Lung
authors.initials: KL
authors.lastname: Wu
authors.affiliation: k Department of Hematology , Erasmus MC Cancer Center , Rotterdam , The Netherlands.
authors.forename: Jeanette K
authors.initials: JK
authors.lastname: Doorduijn
authors.affiliation: l HOVON Data Centre, Erasmus MC , Rotterdam , The Netherlands.
authors.forename: Wendimagegn G
authors.initials: WG
authors.lastname: Alemayehu
authors.affiliation: m Department of Internal Medicine , Gelderse Vallei Hospital , Amersfoort , The Netherlands.
authors.forename: Shulamiet
authors.initials: S
authors.lastname: Wittebol
authors.affiliation: n Department of Clinical Hematology, Third Faculty of Medicine , Charles University Hospital Kralovske Vinohrady , Prague , Czech Republic.
authors.forename: Tomas
authors.initials: T
authors.lastname: Kozak
authors.affiliation: o Lymphoid Malignancies , Maria Sklodowska - Curie Memorial Institute and Oncology Centre , Warszawa , Poland.
authors.forename: Jan
authors.initials: J
authors.lastname: Walewski
authors.affiliation: l HOVON Data Centre, Erasmus MC , Rotterdam , The Netherlands.
authors.forename: Martine C J
authors.initials: MCJ
authors.lastname: Abrahamse-Testroote
authors.affiliation: p Department of Hematology , Academisch Medisch Centrum , Amsterdam , The Netherlands.
authors.forename: Marinus H J
authors.initials: MHJ
authors.lastname: van Oers
authors.affiliation: a Department of Hematology , Rigshospitalet , Copenhagen , Denmark.
authors.forename: Christian H
authors.initials: CH
authors.lastname: Geisler
authors.affiliation: a Department of Hematology , Rigshospitalet , Copenhagen , Denmark.
authors.forename: Carsten U
authors.initials: CU
authors.lastname: Niemann
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000074301:CD52 Antigen / Q000097:blood; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood / Q000188:drug therapy / Q000276:immunology; D010880:Piperidines; D011379:Prognosis; D011720:Pyrazoles / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D000074301:CD52 Antigen; C000613862:CD52 protein, human; D010880:Piperidines; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D000225:Adenine
keywords: CD52; CLL; chemo-immunotherapy; ibrutinib